France’s Sanofi to buy US drugmaker INBRX-101 for about $2.2bn
French healthcare company Sanofi has agreed to buy drug development project INBRX-101 from its parent company Inhibrx for about $2.2 billion in a bid to expand its rare disease business.
POPULAR POSTS
Thousands protest in Valencia over lack of schools after floods
November 25, 2024
COP29 agrees deal to kick-start global carbon credit trading
November 25, 2024
The Girl with the Needle’ wins Camerimage’s Golden Frog
November 25, 2024
LIVE STREAM
